La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Changzhou Qianhong BiopharmaLTD Résultats passés
Nous sommes encore en train de traiter le dernier rapport sur les résultats de cette entreprise.
Passé contrôle des critères 2/6
Changzhou Qianhong BiopharmaLTD has been growing earnings at an average annual rate of 8.7%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 8% per year. Changzhou Qianhong BiopharmaLTD's return on equity is 8.1%, and it has net margins of 12%.
Informations clés
8.7%
Taux de croissance des bénéfices
8.4%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 10.9% |
| Taux de croissance des recettes | 8.0% |
| Rendement des fonds propres | 8.1% |
| Marge nette | 12.0% |
| Dernière mise à jour des bénéfices | 31 Mar 2024 |
Mises à jour récentes des performances passées
Investors Can Find Comfort In Changzhou Qianhong BiopharmaLTD's (SZSE:002550) Earnings Quality
May 02
Recent updates
Changzhou Qianhong BiopharmaLTD (SZSE:002550) Has Affirmed Its Dividend Of CN¥0.12
May 26Changzhou Qianhong Biopharma CO.,LTD (SZSE:002550) Looks Just Right With A 26% Price Jump
May 21Investors Can Find Comfort In Changzhou Qianhong BiopharmaLTD's (SZSE:002550) Earnings Quality
May 02Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?
Mar 24Ventilation des recettes et des dépenses
Comment Changzhou Qianhong BiopharmaLTD gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 24 | 1,667 | 200 | 507 | 94 |
| 31 Dec 23 | 1,814 | 182 | 502 | 97 |
| 30 Sep 23 | 2,121 | 253 | 510 | 94 |
| 30 Jun 23 | 2,223 | 241 | 559 | 99 |
| 31 Mar 23 | 2,360 | 281 | 552 | 98 |
| 01 Jan 23 | 2,304 | 323 | 556 | 88 |
| 30 Sep 22 | 2,155 | 260 | 663 | 75 |
| 30 Jun 22 | 2,139 | 294 | 609 | 74 |
| 31 Mar 22 | 2,036 | 255 | 598 | 71 |
| 01 Jan 22 | 1,875 | 181 | 588 | 71 |
| 30 Sep 21 | 1,873 | -88 | 515 | 70 |
| 30 Jun 21 | 1,886 | -107 | 546 | 69 |
| 31 Mar 21 | 1,913 | -52 | 509 | 68 |
| 31 Dec 20 | 1,668 | -132 | 488 | 69 |
| 30 Sep 20 | 1,694 | 188 | 486 | 55 |
| 30 Jun 20 | 1,487 | 151 | 487 | 61 |
| 31 Mar 20 | 1,454 | 148 | 488 | 64 |
| 31 Dec 19 | 1,675 | 263 | 476 | 65 |
| 30 Sep 19 | 1,462 | 232 | 492 | 67 |
| 30 Jun 19 | 1,490 | 233 | 468 | 67 |
| 31 Mar 19 | 1,350 | 227 | 452 | 66 |
| 31 Dec 18 | 1,322 | 221 | 436 | 67 |
| 30 Sep 18 | 1,312 | 222 | 413 | 68 |
| 30 Jun 18 | 1,223 | 202 | 361 | 96 |
| 31 Mar 18 | 1,160 | 197 | 400 | 16 |
| 31 Dec 17 | 1,065 | 183 | 345 | 64 |
| 30 Sep 17 | 995 | 212 | 324 | 49 |
| 30 Jun 17 | 931 | 226 | 356 | 0 |
| 31 Mar 17 | 863 | 225 | 346 | 0 |
| 31 Dec 16 | 776 | 224 | 333 | 0 |
| 30 Sep 16 | 773 | 250 | 324 | 0 |
| 30 Jun 16 | 788 | 277 | 306 | 0 |
| 31 Mar 16 | 750 | 277 | 295 | 0 |
| 31 Dec 15 | 757 | 267 | 297 | 0 |
| 30 Sep 15 | 730 | 268 | 270 | 0 |
| 30 Jun 15 | 744 | 270 | 265 | 0 |
| 31 Mar 15 | 771 | 259 | 274 | 0 |
| 31 Dec 14 | 815 | 245 | 280 | 0 |
| 30 Sep 14 | 807 | 226 | 244 | 0 |
| 30 Jun 14 | 791 | 205 | 221 | 0 |
| 31 Mar 14 | 832 | 191 | 217 | 0 |
| 31 Dec 13 | 861 | 187 | 210 | 0 |
| 30 Sep 13 | 907 | 188 | 211 | 0 |
Des revenus de qualité: 002550 has a large one-off gain of CN¥36.7M impacting its last 12 months of financial results to 31st March, 2024.
Augmentation de la marge bénéficiaire: 002550's current net profit margins (12%) are higher than last year (11.9%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: 002550's earnings have grown by 8.7% per year over the past 5 years.
Accélération de la croissance: 002550's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: 002550 had negative earnings growth (-28.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).
Rendement des fonds propres
ROE élevé: 002550's Return on Equity (8.1%) is considered low.